News

Dec 06, 2022
Mindset Pharma to Participate in Upcoming Conferences in December 2022
Mindset Pharma to Participate in Upcoming Conferences in December 2022
Dec 06, 2022
Nov 30, 2022
Mindset Pharma CEO, James Lanthier Issues Letter to Shareholders
Mindset Pharma CEO, James Lanthier Issues Letter to Shareholders
Nov 30, 2022
Nov 16, 2022
Mindset Pharma and PharmAla Enter into Exclusive Sales Agreement for the Sale and Distribution of Pharmaceutical Grade Psilocybin
Mindset Pharma and PharmAla Enter into Exclusive Sales Agreement for the Sale and Distribution of Pharmaceutical Grade Psilocybin
Nov 16, 2022
Nov 14, 2022
Mindset Pharma Presents Poster at Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, its Psilocybin-like Lead Drug Candidate
Mindset Pharma Presents Poster at Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, its Psilocybin-like Lead Drug Candidate
Nov 14, 2022
Oct 27, 2022
Mindset Pharma Announces Poster Presentations at Two Upcoming Scientific Conferences
Mindset Pharma Announces Poster Presentations at Two Upcoming Scientific Conferences
Oct 27, 2022
Oct 05, 2022
Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio
Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio
Oct 05, 2022
Sep 27, 2022
Mindset Pharma Provides Strategic Intellectual Property License to Cybin
Mindset Pharma Provides Strategic Intellectual Property License to Cybin
Sep 27, 2022
Sep 14, 2022
Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014
Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014
Sep 14, 2022
Sep 07, 2022
Mindset Pharma Files National Patents Protecting Family 1 Application in 16 Different Countries
Mindset Pharma Files National Patents Protecting Family 1 Application in 16 Different Countries
Sep 07, 2022
Aug 31, 2022
Mindset Pharma Further Expands its IP Portfolio with Three Additional Non-Tryptamine Families of Next-Generation Psychedelic Compounds
Mindset Pharma Further Expands its IP Portfolio with Three Additional Non-Tryptamine Families of Next-Generation Psychedelic Compounds
Aug 31, 2022
Aug 30, 2022
Mindset Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
Mindset Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
Aug 30, 2022
Aug 09, 2022
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders
Aug 09, 2022
Jul 06, 2022
Mindset Pharma Receives Allowance for Patent Application Covering its Short-Duration Novel Psychedelic Medications for The Treatment of Central Nervous System Disorders
Mindset Pharma Receives Allowance for Patent Application Covering its Short-Duration Novel Psychedelic Medications for The Treatment of Central Nervous System Disorders
Jul 06, 2022
Jun 29, 2022
Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation
Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation
Jun 29, 2022
Jun 22, 2022
Mindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular Profile of MSP-1014 Compared to Psilocybin
Mindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular Profile of MSP-1014 Compared to Psilocybin
Jun 22, 2022
Jun 10, 2022
Mindset Pharma Receives Notice of Allowance for Patent Application Covering Psilocin Derivatives for the Treatment of Central Nervous System Disorders
Mindset Pharma Receives Notice of Allowance for Patent Application Covering Psilocin Derivatives for the Treatment of Central Nervous System Disorders
Jun 10, 2022
Jun 07, 2022
Mindset Pharma to Participate in Upcoming Conferences in June 2022
Mindset Pharma to Participate in Upcoming Conferences in June 2022
Jun 07, 2022
May 12, 2022
Mindset Pharma Progresses Plans for Clinical Trials of its Advanced Pre-Clinical Psychedelic, MSP-1014
Mindset Pharma Progresses Plans for Clinical Trials of its Advanced Pre-Clinical Psychedelic, MSP-1014
May 12, 2022
May 04, 2022
Mindset Pharma to Participate in Upcoming Conferences in May 2022
Mindset Pharma to Participate in Upcoming Conferences in May 2022
May 04, 2022
Apr 19, 2022
Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds
Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds
Apr 19, 2022
Apr 05, 2022
Mindset Pharma to Participate in Upcoming Conferences in April 2022
Mindset Pharma to Participate in Upcoming Conferences in April 2022
Apr 05, 2022
Mar 17, 2022
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders
Mar 17, 2022
Mar 03, 2022
Mindset Pharma to Participate in Upcoming Investor Conferences in March 2022
Mindset Pharma to Participate in Upcoming Investor Conferences in March 2022
Mar 03, 2022
Feb 17, 2022
Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions
Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions
Feb 17, 2022
Feb 08, 2022
Mindset Pharma Appoints Dr. Fiona Randall as Senior Vice President of External Alliances and Scientific Strategy
Mindset Pharma Appoints Dr. Fiona Randall as Senior Vice President of External Alliances and Scientific Strategy
Feb 08, 2022
Feb 03, 2022
Mindset Pharma Aims to Treat Broader Addressable Neurology Market by Studying Cognitive Benefits of its “Microdosing” Compounds
Mindset Pharma Aims to Treat Broader Addressable Neurology Market by Studying Cognitive Benefits of its “Microdosing” Compounds
Feb 03, 2022
Jan 25, 2022
Mindset Pharma Enters Manufacturing Agreement with Leading CDMO to Produce Pharmaceutical Grade Batches of Next-Generation Psilocybin Drug Candidate, MSP-1014
Mindset Pharma Enters Manufacturing Agreement with Leading CDMO to Produce Pharmaceutical Grade Batches of Next-Generation Psilocybin Drug Candidate, MSP-1014
Jan 25, 2022
Jan 05, 2022
The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines
The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines
Jan 05, 2022
Jan 04, 2022
Mindset to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022
Mindset to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022
Jan 04, 2022
Subscribe for latest news